Why Wegovy (Semaglutide 2.4 mg) Causes Diarrhea: The Biology Explained

How often does diarrhea occur on Wegovy 2.4 mg?

The rate comes from the Wegovy label: three pooled placebo-controlled trials in 2,116 adults on 2.4 mg and 1,261 on placebo, treated for up to 68 weeks [1]. Diarrhea was reported by 30% on Wegovy and 16% on placebo [1]. Nausea was more common at 44% vs 16%, vomiting was 24% vs 6%, constipation 24% vs 11%, and any gastrointestinal reaction 73% vs 47% [1].

Diarrhea was rarely the reason people stopped. Overall 6.8% of Wegovy-treated adults and 3.2% of placebo-treated adults stopped treatment for an adverse reaction; diarrhea accounted for 0.7% vs 0.1%, behind nausea (1.8% vs 0.2%) and vomiting (1.2% vs 0%) [1].

In the 68-week adolescent trial, with 133 adolescents on Wegovy and 67 on placebo, diarrhea was 22% vs 19% [1]. The label says adverse reaction rates from clinical trials cannot be directly compared with rates in studies of another drug and may not reflect practice [1].

What is known about why it happens?

Semaglutide is a GLP-1 receptor agonist, and the Wegovy label says it delays gastric emptying [1]. The label does not identify a cause for the diarrhea [1].

What the label does describe is a set of gut cautions. Wegovy is not recommended in patients with severe gastroparesis, and the postmarketing reports listed include ileus, intestinal obstruction and severe constipation with fecal impaction [1]. Severe gastrointestinal adverse reactions were reported in 4.1% of Wegovy-treated adults versus 0.9% on placebo in the injection trials [1].

Why Wegovy doses increase gradually

Wegovy starts at 0.25 mg weekly for weeks 1 to 4, then rises to 0.5 mg, 1 mg and 1.7 mg in four-week steps, with 1.7 mg or 2.4 mg as maintenance from week 17 [1]. The label says to follow the escalation schedule to minimize gastrointestinal adverse reactions, and that if a dose is not tolerated during escalation, delaying escalation for 4 weeks can be considered [1]. The label does not report how long individual episodes of diarrhea last [1].

What the label says to watch for

The consequence the label flags is fluid loss. Acute kidney injury due to volume depletion occurred in 0.4 vs 0.2 cases per 100 patient-years (7 vs 4 adults), more often in people with existing kidney impairment and during dose titration, and often after gastrointestinal fluid loss [1]. The label says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1].